Robert Patrick Hirten

Robert Patrick Hirten

Auto-generated profile, based on publicly available information

Robert Patrick Hirten

The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2021 in Annual Review of Medicine
Verified
Journal Article
Closed access
RHRobert P. Hirten
Robert P. Hirten
BSBruce E. Sands
Bruce E. Sands
Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.

22 January 2019 in eLife
Verified
Journal Article
Open access
ECEduardo J Contijoch
Eduardo J Contijoch
GBGraham Britton
Graham Britton
CYChao Yang
Chao Yang
IMIlaria Mogno
Ilaria Mogno
ZLZhihua Li
Zhihua Li
JFJeremiah J Faith
Jeremiah J Faith
To identify factors that regulate gut microbiota density and the impact of varied microbiota density on health, we assayed this fundamental ecosystem property in fecal samples across mammals, human disease, and therapeutic interventions. Physiologic features of the host (carrying capacity) and the fitness of the gut microbiota shape microbiota density. Therapeutic manipulation of microbiota density in mice altered host metabolic and immune homeostasis. In humans, gut microbiota density was reduced in Crohn’s disease, ulcerative colitis, and ileal pouch-anal anastomosis. The gut microbiota in recurrent Clostridium difficile infection had lower density and reduced fitness that were restored by fecal microbiota transplantation. Understanding the interplay between microbiota and disease in terms of microbiota density, host carrying capacity, and microbiota fitness provide new insights into microbiome structure and microbiome targeted therapeutics.

22 February 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RHRobert P Hirten
Robert P Hirten
MDMatteo Danieletto
Matteo Danieletto
LTLewis Tomalin
Lewis Tomalin
KCKatie Hyewon Choi
Katie Hyewon Choi
MZMicol Zweig
Micol Zweig
ZFZahi A Fayad
Zahi A Fayad
Background: Changes in autonomic nervous system function, characterized by heart rate variability (HRV), have been associated with infection and observed prior to its clinical identification. Objective: We performed an evaluation of HRV collected by a wearable device to identify and predict COVID-19 and its related symptoms. Methods: Health care workers in the Mount Sinai Health System were prospectively followed in an ongoing observational study using the custom Warrior Watch Study app, which was downloaded to their smartphones. Participants wore an Apple Watch for the duration of the study, measuring HRV throughout the follow-up period. Surveys assessing infection and symptom-related questions were obtained daily. Results: Using a mixed-effect cosinor model, the mean amplitude of the circadian pattern of the standard deviation of the interbeat interval of normal sinus beats (SDNN), an HRV metric, differed between subjects with and without COVID-19 (P=.006). The mean amplitude of this circadian pattern differed between individuals during the 7 days before and the 7 days after a COVID-19 diagnosis compared to this metric during uninfected time periods (P=.01). Significant changes in the mean and amplitude of the circadian pattern of the SDNN was observed between the first day of reporting a COVID-19–related symptom compared to all other symptom-free days (P=.01). Conclusions: Longitudinally collected HRV metrics from a commonly worn commercial wearable device (Apple Watch) can predict the diagnosis of COVID-19 and identify COVID-19–related symptoms. Prior to the diagnosis of COVID-19 by nasal swab polymerase chain reaction testing, significant changes in HRV were observed, demonstrating the predictive ability of this metric to identify COVID-19 infection.

1 September 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
RHRobert P. Hirten
Robert P. Hirten
Marietta IacucciMarietta Iacucci
Marietta Iacucci
SSShailja Shah
Shailja Shah
SGSubrata Ghosh
Subrata Ghosh
JCJean-Frederic Colombel
Jean-Frederic Colombel

13 July 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MBMatthew Bohm
Matthew Bohm
RXRonghui Xu
Ronghui Xu
YZYiran Zhang
Yiran Zhang
SVSashidhar Varma
Sashidhar Varma
MFMonika Fischer
Monika Fischer
TCthe VICTORY Collaboration
the VICTORY Collaboration
Summary: Background: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)‐antagonist therapy in Crohn's disease (CD).Aim: To compare safety and effectiveness of vedolizumab and TNF‐antagonist therapy in adult CD patients.Methods: Retrospective observational cohort (May 2014–December 2017) propensity score‐weighted comparison of vedolizumab vs TNF‐antagonist therapy (infliximab, adalimumab, certolizumab) in CD. Propensity scores were weighted for age, prior treatments, disease complications, extent and severity, steroid dependence, and concomitant immunosuppressive drug use. The primary outcome was comparative risk for infections or non‐infectious serious adverse events (requiring antibiotics, antivirals, antifungals, hospitalisation, or treatment discontinuation, or resulting in death). Secondary comparative effectiveness outcomes were clinical remission (resolution of CD‐related symptoms), steroid‐free clinical remission and endoscopic remission (absence of ulcers/erosions).Results: We included 1266 patients (n = 659 vedolizumab). Rates of non‐infectious serious adverse events (odds ratio [OR] 0.072, 95% confidence interval [CI] 0.012‐0.242), but not serious infections (OR 1.183, 95% CI 0.786‐1.795), were significantly lower with vedolizumab vs TNF‐antagonist therapy. Safety comparisons for non‐infectious serious adverse events remained significant after adjusting for differences in duration of exposure. No significant difference was observed between vedolizumab and TNF‐antagonist therapy for clinical remission (hazard ratio [HR] 0.932, 95% CI 0.707‐1.228), steroid‐free clinical remission (HR 1.250, 95% CI 0.677‐2.310) or endoscopic remission (HR 0.827, 95% CI 0.595‐1.151). TNF‐antagonist therapy was associated with higher treatment persistence compared with vedolizumab.Conclusions: There was a lower risk of non‐infectious serious adverse events, but not serious infections, with vedolizumab vs TNF‐antagonist therapy, with no significant difference for achieving disease remission.

16 January 2025 in Gastroenterology
Verified
Journal Article
Closed access
RHRobert P. Hirten
Robert P. Hirten
MDMatteo Danieletto
Matteo Danieletto
MSMilagros Sanchez-Mayor
Milagros Sanchez-Mayor
JWJessica K. Whang
Jessica K. Whang
KLKyung Won Lee
Kyung Won Lee
BSBruce E. Sands
Bruce E. Sands